据中国之声《全国新闻联播》报道，国家食品药品监督管理局药品审评中心今天表示，鼓励以临床价值为导向的药物创新，并将进一步加强信息公开力度。

According to the voice of China[The news broadcast]reports,The state food and drug administration drug approval center said today,Encourage guided by clinical value of drug innovation,And will further strengthen the information disclosure.

　　国家食品药品监督管理局药品审评中心28日发布《2012年度中国药品审评报告》。药品审评中心主任张培培用简单的语言向公众介绍了专业性较强药品审评工作。

The state food and drug administration drug approval center 28[Chinese drug approval report for 2012].Zhang Peipei, director of the center for drug evaluation is introduced to the public in simple language professional strong drug approval work.

　　张培培：这个机构有责任向患者和公众说明，为什么这个药可以上市，以及上市的科学依据；向医生和相关的临床机构提供药品使用说明书；向申请人说明批准或不批准的依据。

Zhang Peipei:The agency has the responsibility to explain to patients and the public,Why can this medicine listed,And listed on the scientific basis;Clinical agencies provide drugs to doctors and related instructions;To clarify whether approve or disapprove of the basis.

　　2012年药监局共批准生产615件药品，其中有三个创新药，主要分布在抗肿瘤、心血管和血管性疾病领域。张培培介绍，在药品审评过程中，要将有限的资源向公众最需求的方面倾斜。

Food and drug administration had approved 615 drug production in 2012,There are three innovative drugs,Mainly distributed in anti-tumor/Cardiovascular and vascular disease.Zhang Peipei introduction,In the process of drug approval,Will be the most demand aspects of limited resources to the public.

　　张培培：重点关注对我国重大疾病谱具有较好治疗作用的药物、儿童用药、罕见病药物的研发，对国家重大专项品种实行全程督导，使审评工作更好地落实国家药物创新战略。(记者韩秀)

Zhang Peipei:Focus on major disease in our country has a good therapeutic effect of drugs/Medicine for children/Rare disease of drug research and development,The full supervision of national major projects varieties,Make the review work to better implement the national drug innovation strategy.(The reporter Han Xiu)